VITAL KSK HOLDINGS,INC.
3151・Prime Market・Wholesale Trade
Pharmaceutical Wholesale Business
Core business accounting for approximately 94% of Group sales. Handles pharmaceutical wholesale to hospitals, pharmacies, and other medical institutions.
| Period | Current | Previous | Change |
|---|---|---|---|
| Sales to external customers | ¥572,860 million | ¥564,614 million | ↑ |
| Segment profit (operating profit) | ¥4,920 million | ¥5,163 million | ↓ |
| Segment assets | ¥298,930 million | ¥279,356 million | ↑ |
| Depreciation and amortization | ¥3,373 million | ¥3,233 million | ↑ |
| Segment profit margin | 0.86% | 0.91% | ↓ |
Business Details
Centered on Vital Net Co., Ltd. (Tohoku and Niigata market area) and KSK Co., Ltd. (Kinki region, spanning four prefectures), this segment sells pharmaceuticals, diagnostic reagents, medical equipment, and materials to medical institutions such as hospitals, private practitioners, and pharmacies. As the mainstay segment accounting for approximately 93.8% of the Group's consolidated sales to external customers, Long-Term Vision 2035 targets a reduction to 80% of sales composition and 60% of operating profit composition by FY2035, and the Group is promoting diversification into businesses adjacent to healthcare.
Recent Overview
Profit declined due to the drug price revision and competitive bidding impact, but revenue growth was secured through focus on new drugs and seasonal products.
In FY2026 (ending March 2026), although there was a negative impact from sales declines due to the April 2025 drug price revision and localized competitive bidding, the segment achieved revenue growth (101.5% year-on-year) through a focus on sales of specialty pharmaceuticals centered on anticancer drugs subject to the New Drug Creation Premium, as well as seasonal products such as influenza vaccines and antiallergy drugs. On the profit side, in addition to the impact of sales declines from competitive bidding, an increase in selling, general and administrative expenses amid rising prices led to a decline in profit (95.3% year-on-year).
Key Products
Growth Drivers
- Growth in sales of specialty pharmaceuticals, including products subject to the New Drug Creation Premium centered on anticancer drugs
- Capturing demand for seasonal products such as influenza vaccines and antiallergy drugs
- Thorough per-item price negotiation and strengthened contribution profit management in compliance with distribution improvement guidelines
- Operational efficiency and productivity improvement through DX and AI utilization (order EOS conversion, delivery digitalization, etc.)
- Capturing new revenue through stronger digital marketing (MAPs and the Lab Access Division)
- Focus on distinctive pharmaceutical distribution such as Women's Healthcare Solutions and "Okusuri Aun"
- Building efficient and effective delivery systems tailored to regional characteristics in urban and rural areas
Risks
- Regular drug price reductions from drug price revisions (impact of the April 2026 revision will occur in the next fiscal year)
- Risk of localized sales declines due to the expansion of competitive bidding
- Profit pressure from increases in selling, general and administrative expenses (personnel costs, logistics costs, etc.) amid rising prices
- Decline in drug price levels due to patent expirations of major drugs and promotion of generic drug use
- Increasing demands for advanced information provision and logistics capabilities amid the shift toward specialty pharmaceuticals
- Constraints on pharmaceutical market growth due to continued drug cost containment policies
Last updated: June 19, 2026